Adicet Bio is a clinical-stage biopharmaceutical company developing medicines that target the biology of aging to prevent or treat age-related diseases with the potential to extend healthy lifespan. Co.'s main program selectively inhibits the target of rapamycin complex 1 (TORC1), a conserved pathway that contributes to the age-related decline in function of multiple organ systems. Co.'s product candidate, RTB101, is an oral and selective inhibitor of TORC1. RTB101 inhibits the phosphorylation of multiple targets downstream of TORC1. Co. has licensed the rights to its TORC1 program, including RTB101 alone or in combination with everolimus, from Novartis International Pharmaceutical Ltd. The ACET stock yearly return is shown above.
The yearly return on the ACET stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ACET annual return calculation with any dividends reinvested as applicable (on ex-dates).
|